title: The effect of dalteparin versus unfractionated heparin on the levels of troponin I and creatine kinase isoenzyme MB in elective percutaneous coronary intervention: a multicenter study.
abstract: BACKGROUND
  The aim of this study was to investigate the safety and efficacy of dalteparin during an elective percutaneous coronary intervention (PCI) procedure in a large cohort.
  
  
  METHODS
  In this prospective, randomized, open-label design study, 733 patients undergoing elective PCI were divided into an unfractionated heparin group (group 1, 323 patients) or a dalteparin group (group 2, 410 patients). Blood samples were collected before and 18-24 h after the PCI procedure to determine the serum levels of cardiac troponin I (cTnI) and creatine kinase isoenzyme MB. Major adverse cardiac events (MACEs) and bleeding events during hospitalization were also recorded. Patients with an increased level of serum cTnI before PCI were excluded from the study.
  
  
  RESULTS
  After PCI, the cTnI values were greater than three times the upper limit of normal in 43 cases (13.3%) in group 1 and 52 cases (12.7%) in group 2, without a statistically significant difference between the two groups (P=0.801). An increased creatine kinase isoenzyme MB level of greater than two times the upper limit of normal was found in 10 cases (3.1%) in group 1 and 12 cases (2.9%) in group 2, without a statistically significant difference between the two groups (P=0.894). Postoperative bleeding was observed in nine patients (2.8%) in group 1 and six patients (1.5%) in group 2. Postoperative MACEs were observed in two patients (0.6%) in group 1 and two patients (0.5%) in group 2. There were no significant differences between the two groups with respect to bleeding events or MACEs.
  
  
  CONCLUSIONS
  Our study showed that dalteparin might be as effective and safe as unfractionated heparin for anticoagulation during elective PCI.
authors.affiliation: aDepartment of Cardiology, The Second Hospital of Hebei Medical University bDepartment of Cardiology, The Third Hospital of Shijiazhuang City cDepartment of Cardiology, People's Hospital of Shijiazhuang City dDepartment of Cardiology, The Third Hospital of Hebei Medical University, Shijiazhuang eDepartment of Cardiology, General Hospital of Huabei Oilfield, Renqiu fDepartment of Cardiology, People's Hospital of Xingtai City, Xingtai gDepartment of Cardiology, 252 Hospital of PLA, Baoding, China.
authors.forename: Guangming
authors.initials: G
authors.lastname: Zhang
authors.forename: Wei
authors.initials: W
authors.lastname: Cui
authors.forename: Yongjun
authors.initials: Y
authors.lastname: Li
authors.forename: Xiaoli
authors.initials: X
authors.lastname: Gao
authors.forename: Qingmin
authors.initials: Q
authors.lastname: Wei
authors.forename: Xuebin
authors.initials: X
authors.lastname: Cao
authors.forename: Wenliang
authors.initials: W
authors.lastname: Xiao
authors.forename: Ping
authors.initials: P
authors.lastname: Jiang
authors.forename: Xinhu
authors.initials: X
authors.lastname: Lyu
authors.forename: Fan
authors.initials: F
authors.lastname: Liu
authors.forename: Guoqiang
authors.initials: G
authors.lastname: Gu
authors.forename: Jinming
authors.initials: J
authors.lastname: Liu
mesh_terms: D000368:Aged; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D002681:China; D052279:Creatine Kinase, MB Form / Q000097:blood*; D017985:Dalteparin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced; D006493:Heparin / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects; D011446:Prospective Studies; D013997:Time Factors; D016896:Treatment Outcome; D019210:Troponin I / Q000097:blood*
chemical_list: D000925:Anticoagulants; D015415:Biomarkers; D019210:Troponin I; D006493:Heparin; D052279:Creatine Kinase, MB Form; D017985:Dalteparin